CAQ Corner

You have full text access to this OnlineOpen article

Viral and fungal infections after liver transplantation — Part II

  1. Shimon Kusne†,*,
  2. Janis E. Blair

Article first published online: 28 DEC 2005

DOI: 10.1002/lt.20667

Issue

Liver Transplantation

Liver Transplantation

Volume 12, Issue 1, pages 2–11, January 2006

Additional Information

How to Cite

Kusne, S. and Blair, J. E. (2006), Viral and fungal infections after liver transplantation — Part II. Liver Transpl, 12: 2–11. doi: 10.1002/lt.20667

Author Information

  1. Division of Infectious Diseases, Mayo Clinic, Scottsdale, AZ

  1. †

    Telephone: 480-342-0161; FAX: 480-342-0115

*Division of Infectious Diseases, Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054

Publication History

  1. Issue published online: 28 DEC 2005
  2. Article first published online: 28 DEC 2005
  3. Manuscript Accepted: 26 OCT 2005
  4. Manuscript Received: 19 OCT 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (121K)

REFERENCES

  • 1
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741–1751.
  • 2
    Rubin RH. The direct and indirect effects of infection in liver transplantation: pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis 2002; 22: 125–154.
  • 3
    George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, et al. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103: 106–113.
  • 4
    O'Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988; 2: 302–305.
  • 5
    Ljungman P, Plotkin SA. Workshop on CMV disease: definitions, clinical severity scores, and new syndromes. Scand J Infect Dis 1995; 99: S87–S89.
  • 6
    Gaeta A, Nazzari C, Angeletti S, Lazzarini M, Mazzei E, Mancini C. Monitoring for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes. J Med Virol 1997; 53: 189–195.
    Direct Link:
  • 7
    Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232–1237.
  • 8
    Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1999; 1: 187–203.
    Direct Link:
  • 9
    Keating MR. Antiviral agents. Mayo Clin Proc 1992; 67: 160–178.
  • 10
    Zanetta G, Maurice-Estepa L, Mousson C, Justrabo E, Daudon M, Rifle G, et al. Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation. Transplantation 1999; 67: 1376–1378.
  • 11
    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645–649.
  • 12
    Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779–785.
  • 13
    Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. The Oral Ganciclovir International Transplantation Study Group: randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729–33. Erratum in: Lancet 1998;351:454.
  • 14
    Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Valganciclovir Solid Organ Transplant Study Group: efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611–620.
    Direct Link:
  • 15
    Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, et al. Boston Center for Liver Transplantation CMVIG Study Group: cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119: 984–991.
  • 16
    Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1057–1059.
  • 17
    Kusne S, Grossi P, Irish W, St George K, Rinaldo C, Rakela J, et al. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125–1131.
  • 18
    Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002 Apr 1; 185: 854–860. Epub 2002 Mar 19.
  • 19
    Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995; 123: 18–26.
  • 20
    Randhawa PS, Markin RS, Starzl TE, Demetris AJ. Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients: clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 1990; 14: 538–547.
  • 21
    Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 1999; 68: 1517–1525.
  • 22
    Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002; 236: 429–436.
  • 23
    Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW, Sibley RK, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262–4279.
  • 24
    Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 9–18.
  • 25
    Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723–1728.
  • 26
    Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346–1353.
  • 27
    Manez R, Breinig MK, Linden P, Kusne S, Torre-Cisneros J, Wilson J, et al. Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 1994; 7: S235–S237.
    Direct Link:
  • 28
    Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant. 2001; 1: 103–108.
  • 29
    Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587.
  • 30
    Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451–1456.
  • 31
    Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–1555.
  • 32
    Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas: Recent Results. Cancer Res 2002; 159: 123–133.
  • 33
    Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67: 132–143.
  • 34
    Feldman S, Stokes DC. Varicella zoster and herpes simplex virus pneumonias. Semin Respir Infect 1987; 2: 84–94.
  • 35
    Kusne S, Pappo O, Manez R, Pazin G, Carpenter B, Fung JJ, et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation 1995; 60: 619–621.
  • 36
    Kusne S, Schwartz M, Breinig MK, Dummer JS, Lee RE, Selby R, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163: 1001–1007.
  • 37
    Cirelli R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996; 29: 141–151.
  • 38
    Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002; 186: S40–S46.
  • 39
    Cames B, Rahier J, Burtomboy G, de Ville de Goyet J, Reding R, Lamy M, et al. Acute adenovirus hepatitis in liver transplant recipients. J Pediatr 1992; 120: 33–37.
  • 40
    Koneru B, Jaffe R, Esquivel CO, Kunz R, Todo S, Iwatsuki S, et al. Adenoviral infections in pediatric liver transplant recipients. JAMA 1987; 258: 489–492.
  • 41
    Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992; 165: 170–174.
  • 42
    Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, et al. Human beta-herpesvirus interactions in solid organ transplnat recipients. J Infect Dis 2001 Jan 15; 183: 179–184. Epub 2000 Dec 15.
  • 43
    Razonable RR, Rivero A, Brown RA, Hart GD, Espy MJ, van Cruijsen H, et al. Detection of simultaeous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17: 114–120.
    Direct Link:
  • 44
    Okuno T, Takahashi K, Balachandra K, Shiraki K, Yamanishi K, Takahashi M, et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol. 1989; 27: 651–653.
  • 45
    Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002; 8: 651–658.
    Direct Link:
  • 46
    Lautenschlager I, Linnavuori K, Hockerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000; 69: 2561–2566.
  • 47
    Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997; 64: 674–678.
  • 48
    Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000; 69: 2474–2479.
  • 49
    Rogers J, Rohal S, Carrigan DR, Kusne S, Knox KK, Gayowski T, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69: 2566–2573.
  • 50
    Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000; 342: 1027–1038.
  • 51
    Pozo F, Tenorio A, de la Mata M, de Ory F, Torre-Cisneros J. Persistent human herpesvirus 8 viremia before Kaposi's sarcoma development in a liver transplant recipient. Transplantation 2000; 70: 395–397.
  • 52
    Kadry Z, Bronsther O, Van Thiel DH, Randhawa P, Fung JJ, Starzl TE. Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant 1993; 7: 188–194.
  • 53
    Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339: 1358–1363.
  • 54
    Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, Gao SJ, et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 1997; 90: 2826–2829.
  • 55
    Jenkins FJ, Hoffman LJ, Liegey-Dougall A. Reactivation of and primary infection with human herpesvirus 8 among solid-organ transplant recipients. J Infect Dis 2002; 185: 1238–1243. Epub 2002 Apr 9.
  • 56
    Verucchi G, Calza L, Trevisani F, Zambruni A, Tadolini M, Giuliani R, et al. Human herpesvirus-8-related Kaposi's sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. Transpl Infect Dis 2005; 7: 34–37.
    Direct Link:
  • 57
    Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14. Epub 2001 Nov 26.
  • 58
    Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999; 1: 273–283.
    Direct Link:
  • 59
    Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy, 2005. Expert Opin Pharmacother 2005; 6: 1657–1668.
  • 60
    Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003; 37: 17–25. Epub 2003 Jun 20.
  • 61
    Wajszczuk CP, Dummer JS, Ho M, Van Thiel DH, Starzl TE, Iwatsuki S, et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347–353.
  • 62
    Fung JJ. Fungal infection in liver transplantation. Transpl Infect Dis 2002; 4: 18–23.
    Direct Link:
  • 63
    Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644–652.
  • 64
    Singh N, Gayowski T, Wagener MM, Doyle H, Marino IR. Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Clin Infect Dis 1997; 24: 179–184.
  • 65
    Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375–382.
  • 66
    Castaldo P, Stratta RJ, Wood RP, Markin RS, Patil KD, Shaefer MS, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149–156.
  • 67
    Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926–934.
  • 68
    Fortun J, Martin-Davila P, Moreno S, Barcena R, de Vicente E, Honrubia A, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813–819. Epub 2003 Oct 16.
  • 69
    Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729–737.
  • 70
    Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David Colby W. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003; 76: 977–983.
  • 71
    Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intavenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74: 688–695.
  • 72
    Biancofiore G, Bindi ML, Baldassarri R, Romanelli AM, Catalano G, Filipponi F, et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl Int 2002; 15: 341–347. Epub 2002 Jun 20.
    Direct Link:
  • 73
    Singhal S, Ellis RW, Jones SG, Miller SJ, Fisher NC, Hastings JG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000; 6: 588–595.
    Direct Link:
  • 74
    Kusne S, Tobin D, Pasculle AW, Van Thiel DH, Ho M, Starzl TE. Candida carriage in the alimentary tract of liver transplant candidates. Transplantation 1994; 57: 398–402.
  • 75
    Fortun J, Lopez-San Roman A, Velasco JJ, Sanchez-Sousa A, de Vicente E, Nuno J, et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 1997; 16: 314–318.
  • 76
    Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023–2029.
  • 77
    Kusne S, Torre-Cisneros J, Manez R, Irish W, Martin M, Fung J, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1379–1383.
  • 78
    Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996; 100: 171–178.
  • 79
    Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716–720.
  • 80
    Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2: 575–580.
    Direct Link:
  • 81
    Vilchez R, Shapiro R, McCurry K, Kormos R, Abu-Elmagd K, Fung J, et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003 May; 16: 336–340. Epub 2003 Mar 4.
    Direct Link:
  • 82
    Jabbour N, Reyes J, Kusne S, Martin M, Fung J Cryptococcal meningitis after liver transplantation. Transplantation 1996; 61: 146–149.
  • 83
    Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al, Infectious Diseases Society of America: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710–718. Epub 2000 Apr 20.
  • 84
    Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001; 33: 1536–1544. Epub 2001 Oct 4.
View Full Article (HTML) Get PDF (121K)